FindTrial
Sign In

Effect of Levamisole as a promising immunomodulator in the management of Subacute sclerosing panencephalitis: Randomized controlled trial

Promising new treatment option in Subacte Sclerosing Panencephalitis - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2025/03/083429
Enrollment
40
Registered
2025-03-25
Start date
Unknown
Completion date
Unknown
Last updated
2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E830- Disorders of copper metabolism

Interventions

Intervention1: Levamisole: 150 mg levamisole orally daily once for one month Control Intervention1: Placebo: look alike placebo multi-vitamin tablet orally once a day for one month

Sponsors

Institute of Eminence
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: All consecutive patients of SSPE (diagnosed as per the Dyken’s criteria) in the early stage (stages I II), attending neurology medicine of paediatrics and neurology OPD after a duly and informed consent will be included

Exclusion criteria

Exclusion criteria: Patients in the advanced stage (III IV) of the disease

Design outcomes

Primary

MeasureTime frame
Post intervention serum and CSF measles IgG antibodies titre, neopterin level and other investigations along with all clinical evaluations including cognitive and behavioural changesTimepoint: at baseline and at 4 weeks—

Secondary

MeasureTime frame
other investigations along with all clinical evaluations including cognitive & behavioural changesTimepoint: at baseline & at 4 weeks—

Countries

India

Contacts

Public ContactDr Neetu Rani Dhiman

Institute of Medical Sciences, Banaras Hindu University

gyanpurineetu@gmail.com7880301002

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026